

Dermatology through the Circle of Life





Hidradenitis suppurativa

terminology

Hidradenitis suppurativa (HS)

Acne inversa

Prevalence

•1%

diagnosis

 Clinical diagnosis (without the use of laboratory tests)

- 1. Typical patient
- 2. Typical risk factors
- 3. Typical skin lesions at typical sites

Typical patient

- Post pubertal (20-30)
- Female (3:1)



Typical risk factors

- Obesity
- Smoking





Typical skin lesions at typical sites

- Deep seated inflammatory, painful nodules
- Abscesses
- Ulceration
- Sinus tracts
- Discharge (pussy and smelly)
- Scarring



Double comedones



Deep painful nodules





abscesses



Sinus tracts with discharge





scarring



chronic








Double comedones





Typical Body sites



Diagnosis: Summary

- 1. More than one inflamed lesion
- 2. Chronic and recurrent
- 3. Bilateral
- 4. In milk lines



THE LONG HS JOURNEY:2



of HS patients had more than

7 FAMILY PHYSICIAN VISITS

before diagnosis



of HS patients had more than

10 MEDICAL EMERGENCY VISITS

before diagnosis



Average age of diagnosis is



YEARS

Average referral wait time for dermatologist is



180 DAYS



has at least one misdiagnosis for HS

MISDIAGNOSES INCLUDE:

Skin infections • In-grown hair • Spider bite
Sexually transmitted infection • Dairy or gluten intolerance

MAIN HS CARE PROVIDERS:²













HS Pathogeneses



Hurley staging system





Stage III.

Multiple interconnected tracts and abscesses throughout the entire affected area



Stage II.

One or more widely separated recurrent abscesses with a tract and cicatrization

PSYCHOLOGICAL impact

- DLQI much worse than that of many other dermatologic diseases (chronic urticaria, psoriasis, atopic dermatitis, and even neurofibromatosis)
- **Symptoms:** soreness, stinging, itching, malodorous discharge
- **Stigma:** because of the location, of lesions in intimate sites
- ❖ Lack of medical care: incorrect diagnosis or the hesitancy of patients to disclose the symptoms or signs of HS
- **Economic** disabilities

Quality of Life and Hidradenitis

Table 3. Mean Dermatology Life Quality Index (DLQI) scores reported in different conditions (adapted from Finlay³)


Condition	DLQI score
Hidradenitis suppurativa	8.9
Alopecia ¹⁵	8.3
Acne ¹⁶	7.5
Psoriasis ¹⁷ (mild to moderate)	7.0
Hailey-Hailey disease ¹⁸	6.1
Darier's disease ¹⁸	5.9
Vascular anomalies of face ¹⁹	5.6
Atopic dermatitis ²⁰	5.5
DLQI maximum score	30

J.M. Von Der Werth, G.B.E. Jemec (2001) Morbidity in patients with hidradenitis suppurativa British Journal of Dermatology 144 (4), 809–813.





Impairment of Sexual Life



General considerations

Medication

Surgery

General measures

Table VI. General treatment suggestions for all hidradenitis suppurativa patients regardless of Hurley stage

Avoidance of tight-fitting clothing Nonnarcotic analgesics Reassurance Smoking cessation Stress management Support group referral Weight loss





01

Antibiotics

02

Biologics (Adalimumab)

03

Other

Medications


Antibiotics Skin microbiological cultures are not useful



Use for 3 months - reintroduce with recurrence (if they were effective at the last time of use)

No evidence for the use of other antibiotics

biologics



Adalimumab should be considered as the first choice biologic agent in moderate/severe HS after failure of conventional treatments. (2,B)

Infliximab should be considered as the second-line biologic for moderate/ severe HS (2,B) Anakinra (2,B) has been shown to be effective and should be considered as a third-line biologic for moderate/severe HS.

Ustekinumab (4,C) is potentially effective in moderate/severe HS

Etanercept is not effective in HS (2,B)

Biologics

JAMA Dermatology Clinical Evidence Synopsis

Interventions for Hidradenitis Suppurativa Updated Summary of an Original Cochrane Review

John R. Ingram, DM, MRCP

BOTTOM LINE There is high-quality evidence of benefit from adalimumab given weekly, while every other week dosing is ineffective, with reductions in Dermatology Life Quality Index (DLQI) scores compared with placebo of 2.8 points (95% CI, -3.7 to -2.0 points) and 1.6 points (95% CI, -3.9 to 0.6 points), respectively. Moderate-quality evidence suggests that infliximab is beneficial; RCT evidence for other interventions was lower in quality or absent, limiting further conclusions.

Comorbidities/risk factors

- Smoking
- Obesity
- Hypertriglyceridemia
- Diabetes
- Hypertension
- Metabolic syndrome
- Cardiovascular disease
- Depression
- Crohn's disease
- Spondyloarthritis

Careful assessment and referral / pre-screening if indicated

Surgery

- ❖ In acute situations (tense and painful abscesses)/fluctuating lesions = Incision and draining (4,C)
- NB: NOT sole treatment recurrence inevitable!
- **❖ Limited** areas = limited excision and deroofing (4,C)
- **❖ Widespread** = wide excision (4,C)
- **Chronic HS** without inflammation = excision to prevent recurrence (5,D)
- **CO2 laser** can be used as alternative (4,C)



Practical Treatment algorithm for everyday practise


Diagnosis


General measures

Weight loss, smoking, dressings, pain relief, superinfection


Grading

Hurley AND patients reported outcomes






Multidisciplinary treatment Surgeon General Physician Family **Psychologist HS** patient practitioner Dermatologist






Dermatology through the Circle of Life



Skin cancer



Classification

Sarcoma

BCC (80%) Non-melanoma skin cancers **SCC (20%) Primary** Malignant skin tumours Melanoma Kaposi

BCC/SCC incidence


- Underestimated!!!
- BCC most common cancer in the United States
- SCC second most common skin cancer
- 3.5 million new cases (BCC/SCC) diagnosed in 2006 in the USA
- 40% of men and 30% of women will develop BCC

Melanoma incidence


Table 4.1 Age-standardized incidence of melanoma in selected countries of the world

	Incidence rate ^a per 100,000	
Country	Male	Female
Columbia, Cali	2.5	2.7
Canada	8.5	7.5
United States, SEER White	15.4	11.6
United States, SEER Black	1.0	0.5
India, Mumbai (Bombay)	0.3	0.2
Israel, Jews	11.7	11.3
Israel, Non-Jews	1.0	0.9
Japan, Hiroshima	0.4	0.5
China, Beijing	0.3	0.2
Czech Republic	8.1	7.9
Denmark	10.5	13.4
Finland	8.0	6.7
Germany, Saarland	6.3	6.1
The Netherlands	8.0	10.9
Poland, Warsaw City	4.1	4.1
Spain, Murcia	4.1	5.4
Sweden	11.8	11.9
UK, England	5.8	7.4
UK, Scotland	7.1	9.9
Australia, New South Wales	36.9	25.9
Australia, Queensland	51.1	38.1
New Zealand	32.8	30.6
^a Age standardized at world µ Source: Cancer Incidence in IARC Scientific Publications;	Five Continent	s, Vol. III. Lyon:

Melanoma epidemic



Melanoma deaths



South Africa Incidence

Mean age-standardised annual incidence of reported squamous cell carcinoma of the skin (SCC), basal cell carcinoma (BCC) and cutaneous melanoma (CM) per 100,000 persons in White populations of South Africa, 2000-2004.

BCC

198.3 (male)

112.8 (female)

SCC

69.5 (male)

31.8 (female)

CM

20.5 (male)

16.5 (female)

Skin malignancies are extremely common in South Africa

Dermatologists see:

BCC - every day


SCC - every week

MM - every month

Why the high incidence in South Africa?




South African Renewable Energy Resource Database - Annual Solar Radiation













Basal Cell Carcinoma

- nodule with ulceration
- pearly with telangiectatic vessels
- contact bleeding
- metastases : extremely rare
- locally destructive
- perineural spread → into skull























HIGH-RISK MASK AREA OF THE FACE



Treatment

- excision (Mohs' surgery)
- cryotherapy
- RT
- C&C
- intralesional interferon
- PDT
- imiquimod
- 5 FU


Learning points

- Catch lesions early
- Do not sit and watch doubtful lesions near the eye
- Non healing ulcers



Squamous cell carcinoma (SCC)

- Invasion
- Metastases: regional lymph nodes, beyond (mucosal)
- UV-light, smoking & HPV
- Keratotic lump
- Non-healing ulcer
- Rolled edge
- UV-areas


















Treatment

- excision (mainstay)
- radiation therapy
 - surgery contraindicated
 - aggressive
 - metastatic disease

Learning points


- Biopsy
 - Non healing ulcers
 - Enlarging crusted lesions
 - Persistent keratotic lesion
 - Recurrent scab formation
- Fully examine sun damaged skin
- Remember the lips

Melanoma



Melanoma, identification and diagnosis





homogeneous (two or more tones: brown, reddish, dark)

asymmetric

ABCD <u>E</u> <u>F</u>

- **A** asymmetry
- **B** irregular **b**order
- **C** more that 2 − 3 **c**olours / **c**hange
- **D d**iameter > 6mm (20% < 6mm)
- **E** irregular *e*levation, *e*volution, *e*xamine
- F funny looking






Diagram showing where melanoma is most likely to develop on the body Copyright @ CancerHelp UK

<u>Important</u>

- Good lighting and magnification
- Train your eye
- Take a good history
- Identify high risk patients refer, self examination
- Take note of any change

Who is at higher risk?

- Personal history of melanoma
- Positive family history of melanoma
- Numerous nevi
- Dysplastic nevi
- Fair skin
- Red hair, blue eyes
- Nonmelanoma skin cancer
- Excessive UV exposure
- Indoor tanning
- Age
- Sex

What should we tell our patients?

Recognizing melanoma – ABCDE

• New and changing nevi

• Role of self-skin examination

Ugly duckling sign



Ugly duckling sign




Figure 1. The "ugly duckling" nevus in case 1 deserves special attention, whereas a similar nevus would be considered normal in case 2, since most nevi share the same features. Conversely, the ugly duckling nevus in case 2 would be considered normal in case 1.


Ugly duckling sign



Dermatoscopy








Mole mapping






Malignant Melamona In Situ





Superficial spreading melanoma








Nodular melanoma





Amelanotic melanoma





Acral melanomas
















Metastatic melanoma



TREATMENT

- two stage procedure
- conservative excision / biopsy to establish diagnosis
 & Breslow

- therapeutic excision
- margin \equiv depth 1-3 cm
- elective LN excision : NO
- therapeutic LN excision : probably YES
- sentinel LN dissection : probably YES

Prevention of Skin Cancer

- avoid sunburn
- avoid UV-light between 11h00 15h00
- protective clothing
- Sunscreen: SPF 30
- early diagnosis = patient / physician knowledge

What must you now be able to do?

- Identify high risk patients
- Examine patient
- ABCDE 'ugly duckling'
- If any doubt ---- REFER early
- Educate people self examination, sunprotection



SUNÁWARE

Simple steps to prevent and detect skin cancers

- Avoid *unprotected* UV exposure, seek shade
- Wear sun protective clothing, a hat and sunglasses
- Apply sunscreen generously and often
- Routinely check skin and report changes
- Educate yourself and others



